Novartis Ag

Boehringer Ingelheim International Gmbh

Ablynx N.v.

Karen Cromie

Marie-Ange Buyse

Bruno Dombrecht

Stephanie Staelens

Soren Steffensen

Steven John Charlton

Michelle Bradley

Zarin Brown

Vittoria Zinzalla

Beatrijs Strubbe

Carlo Boutton

Judith Baumeister

Gino Van Heeke

Veerle Snoeck

Gino Anselmus Van Heeke

Marie-Paule Bouche

Klaus-Peter Kuenkele

Joost Alexander Kolkman

Jing Li

Seth Alexander Ettenberg

David Raymond Stover

Kris Meerschaert

Jingxin Zhang

The invention provides LRP5-binding polypeptides, and more specifically LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.

Polypeptides antagonizing Wnt signaling in tumor cells

The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.

Biparatopic polypeptides antagonizing Wnt signaling in tumor cells

The present invention relates to polypeptides directed against or specifically binding to C&#x2014;X&#x2014;C Motif chemokine receptor 2 (CXCR2) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.

Chemokine receptor binding polypeptides

The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.

The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.

Nucleic acids encoding chemokine receptor binding polypeptides

The present invention relates to polypeptides directed against or specifically binding to CXC chemokine receptor 2 ('CXCR2') and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.

Methods of treatment using chemokine receptor binding polypeptides

The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also 'DR5'), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as 'NB agents') and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders.

Biologic compounds directed against death receptor 5

Growing community of inventors

Merelbeke, Belgium

Karen Cromie